MX2017001229A - Receptores de antigenos quimericos especificos de egfrviii para inmunoterapia de cancer. - Google Patents

Receptores de antigenos quimericos especificos de egfrviii para inmunoterapia de cancer.

Info

Publication number
MX2017001229A
MX2017001229A MX2017001229A MX2017001229A MX2017001229A MX 2017001229 A MX2017001229 A MX 2017001229A MX 2017001229 A MX2017001229 A MX 2017001229A MX 2017001229 A MX2017001229 A MX 2017001229A MX 2017001229 A MX2017001229 A MX 2017001229A
Authority
MX
Mexico
Prior art keywords
chimeric antigen
antigen receptors
cancer immunotherapy
egfrviii
specific chimeric
Prior art date
Application number
MX2017001229A
Other languages
English (en)
Inventor
Schiffer-Mannioui Cecile
Original Assignee
Pfizer
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Pfizer filed Critical Pfizer
Publication of MX2017001229A publication Critical patent/MX2017001229A/es

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/2863—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against receptors for growth factors, growth regulators
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K35/00—Medicinal preparations containing materials or reaction products thereof with undetermined constitution
    • A61K35/12—Materials from mammals; Compositions comprising non-specified tissues or cells; Compositions comprising non-embryonic stem cells; Genetically modified cells
    • A61K35/14—Blood; Artificial blood
    • A61K35/17—Lymphocytes; B-cells; T-cells; Natural killer cells; Interferon-activated or cytokine-activated lymphocytes
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/46—Cellular immunotherapy
    • A61K39/461—Cellular immunotherapy characterised by the cell type used
    • A61K39/4611—T-cells, e.g. tumor infiltrating lymphocytes [TIL], lymphokine-activated killer cells [LAK] or regulatory T cells [Treg]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/46—Cellular immunotherapy
    • A61K39/463—Cellular immunotherapy characterised by recombinant expression
    • A61K39/4631—Chimeric Antigen Receptors [CAR]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/46—Cellular immunotherapy
    • A61K39/464—Cellular immunotherapy characterised by the antigen targeted or presented
    • A61K39/4643—Vertebrate antigens
    • A61K39/4644—Cancer antigens
    • A61K39/464402—Receptors, cell surface antigens or cell surface determinants
    • A61K39/464403—Receptors for growth factors
    • A61K39/464404—Epidermal growth factor receptors [EGFR]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K48/00—Medicinal preparations containing genetic material which is inserted into cells of the living body to treat genetic diseases; Gene therapy
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/705—Receptors; Cell surface antigens; Cell surface determinants
    • C07K14/70503—Immunoglobulin superfamily
    • C07K14/7051—T-cell receptor (TcR)-CD3 complex
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/705—Receptors; Cell surface antigens; Cell surface determinants
    • C07K14/70503—Immunoglobulin superfamily
    • C07K14/70517—CD8
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/705—Receptors; Cell surface antigens; Cell surface determinants
    • C07K14/70578—NGF-receptor/TNF-receptor superfamily, e.g. CD27, CD30, CD40, CD95
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K2239/00—Indexing codes associated with cellular immunotherapy of group A61K39/46
    • A61K2239/46—Indexing codes associated with cellular immunotherapy of group A61K39/46 characterised by the cancer treated
    • A61K2239/47—Brain; Nervous system
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/20—Immunoglobulins specific features characterized by taxonomic origin
    • C07K2317/24—Immunoglobulins specific features characterized by taxonomic origin containing regions, domains or residues from different species, e.g. chimeric, humanized or veneered
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/52—Constant or Fc region; Isotype
    • C07K2317/53—Hinge
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/56—Immunoglobulins specific features characterized by immunoglobulin fragments variable (Fv) region, i.e. VH and/or VL
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/60—Immunoglobulins specific features characterized by non-natural combinations of immunoglobulin fragments
    • C07K2317/62—Immunoglobulins specific features characterized by non-natural combinations of immunoglobulin fragments comprising only variable region components
    • C07K2317/622—Single chain antibody (scFv)
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
    • C07K2317/73—Inducing cell death, e.g. apoptosis, necrosis or inhibition of cell proliferation
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2319/00—Fusion polypeptide
    • C07K2319/01—Fusion polypeptide containing a localisation/targetting motif
    • C07K2319/03—Fusion polypeptide containing a localisation/targetting motif containing a transmembrane segment
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2319/00—Fusion polypeptide
    • C07K2319/33—Fusion polypeptide fusions for targeting to specific cell types, e.g. tissue specific targeting, targeting of a bacterial subspecies
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N2333/00—Assays involving biological materials from specific organisms or of a specific nature
    • G01N2333/435—Assays involving biological materials from specific organisms or of a specific nature from animals; from humans
    • G01N2333/705—Assays involving receptors, cell surface antigens or cell surface determinants
    • G01N2333/71—Assays involving receptors, cell surface antigens or cell surface determinants for growth factors; for growth regulators

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Immunology (AREA)
  • Organic Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Cell Biology (AREA)
  • Molecular Biology (AREA)
  • Genetics & Genomics (AREA)
  • Biochemistry (AREA)
  • Biophysics (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Animal Behavior & Ethology (AREA)
  • Epidemiology (AREA)
  • Zoology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Toxicology (AREA)
  • Mycology (AREA)
  • Microbiology (AREA)
  • Dermatology (AREA)
  • Oncology (AREA)
  • Engineering & Computer Science (AREA)
  • Biotechnology (AREA)
  • Biomedical Technology (AREA)
  • Developmental Biology & Embryology (AREA)
  • Virology (AREA)
  • Hematology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
  • Peptides Or Proteins (AREA)
  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)

Abstract

La presente invención se refiere a receptores de antígeno quimérico (CAR) que son proteínas quiméricas recombinantes capaces de redirigir especificidad de célula inmune y reactividad hacia antígenos de membrana seleccionados, y más en particular en donde unión a ligando extracelular es un scFV derivado de un anticuerpo monoclonal de EGFRvlll, confiriendo inmunidad específica contra células EGFRvIII positivas. Las células inmunes manipuladas de TCR KO dotadas con dichos CARs son particularmente adecuadas para tratar cáncer pulmonar, cánceres anales y glioblastoma multiforme.
MX2017001229A 2014-07-29 2015-07-29 Receptores de antigenos quimericos especificos de egfrviii para inmunoterapia de cancer. MX2017001229A (es)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
DKPA201470466 2014-07-29
PCT/EP2015/067439 WO2016016341A1 (en) 2014-07-29 2015-07-29 EGFRvIII SPECIFIC CHIMERIC ANTIGEN RECEPTORS FOR CANCER IMMUNOTHERAPY

Publications (1)

Publication Number Publication Date
MX2017001229A true MX2017001229A (es) 2017-05-01

Family

ID=51300485

Family Applications (1)

Application Number Title Priority Date Filing Date
MX2017001229A MX2017001229A (es) 2014-07-29 2015-07-29 Receptores de antigenos quimericos especificos de egfrviii para inmunoterapia de cancer.

Country Status (12)

Country Link
US (1) US20170275366A1 (es)
EP (1) EP3174556A1 (es)
JP (1) JP2017522884A (es)
KR (2) KR20180125632A (es)
CN (1) CN107074973A (es)
AU (1) AU2015295346A1 (es)
BR (1) BR112017001818A2 (es)
CA (1) CA2956307A1 (es)
IL (1) IL250339A0 (es)
MX (1) MX2017001229A (es)
RU (1) RU2017102769A (es)
WO (1) WO2016016341A1 (es)

Families Citing this family (40)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DK3405490T3 (da) 2016-01-21 2022-01-10 Pfizer Mono- og bispecifikke antistoffer mod epidermal vækstfaktorreceptor variant iii og cd3 og anvendelser deraf
SG11201805872SA (en) * 2016-01-21 2018-08-30 Pfizer Chimeric antigen receptors targeting epidermal growth factor receptor variant iii
AU2017296237A1 (en) * 2016-07-15 2019-01-03 Poseida Therapeutics, Inc. Chimeric antigen receptors (CARS) specific for MUC1 and methods for their use
JP2019536437A (ja) 2016-10-03 2019-12-19 ジュノー セラピューティクス インコーポレイテッド Ｈｐｖ特異的結合分子
CA3039014A1 (en) 2016-10-04 2018-04-12 Precision Biosciences, Inc. Co-stimulatory domains for use in genetically-modified cells
CN110520530A (zh) * 2016-10-18 2019-11-29 明尼苏达大学董事会 肿瘤浸润性淋巴细胞和治疗方法
CN108276493B (zh) * 2016-12-30 2023-11-14 南京传奇生物科技有限公司 一种嵌合抗原受体及其应用
JP2020516276A (ja) * 2017-04-14 2020-06-11 ザ ジェネラル ホスピタル コーポレイション 腫瘍微小環境を標的にするキメラ抗原受容体ｔ細胞
KR102302714B1 (ko) * 2017-04-26 2021-09-17 주식회사 파이안바이오테크놀로지 신호전달 막단백질의 경막 부위를 이용한 목적단백질의 인간세포 막 표면 발현 방법
CN111954679A (zh) 2017-10-03 2020-11-17 朱诺治疗学股份有限公司 Hpv特异性结合分子
CN109694854B (zh) * 2017-10-20 2023-11-21 亘喜生物科技（上海）有限公司 通用型嵌合抗原受体t细胞制备技术
CN109750035B (zh) * 2017-11-02 2020-06-05 上海邦耀生物科技有限公司 靶向并引导Cas9蛋白高效切割TCR及B2M基因座的sgRNA
WO2019114751A1 (zh) * 2017-12-12 2019-06-20 科济生物医药（上海）有限公司 免疫效应细胞和辐射联用治疗肿瘤
JP2021520211A (ja) 2018-04-05 2021-08-19 ジュノー セラピューティクス インコーポレイテッド 組換え受容体を発現するｔ細胞、関連ポリヌクレオチド、および方法
JP2021520202A (ja) 2018-04-05 2021-08-19 ジュノー セラピューティクス インコーポレイテッド 組換え受容体を発現する細胞の作製方法および関連組成物
PE20201345A1 (es) 2018-04-05 2020-11-25 Juno Therapeutics Inc Receptores de celulas t, y celulas disenadas que expresan los mismos
CN112292400A (zh) * 2018-04-13 2021-01-29 桑格摩生物治疗法国公司 对白介素-23受体特异的嵌合抗原受体
MX2020012028A (es) * 2018-05-11 2021-03-29 Crispr Therapeutics Ag Metodos y composiciones para tratar el cancer.
US20220403001A1 (en) 2018-06-12 2022-12-22 Obsidian Therapeutics, Inc. Pde5 derived regulatory constructs and methods of use in immunotherapy
CN114957475B (zh) * 2018-09-26 2023-06-20 福州拓新天成生物科技有限公司 抗b7-h3的单克隆抗体及其在细胞治疗中的应用
WO2020068366A1 (en) 2018-09-26 2020-04-02 W. L. Gore & Associates, Inc. Cell encapsulation devices with controlled cell bed thickness
EP3870600A1 (en) 2018-10-24 2021-09-01 Obsidian Therapeutics, Inc. Er tunable protein regulation
CN109485731A (zh) * 2018-11-02 2019-03-19 广东克瑞斯普生物科技有限公司 一种靶向EGFRvIII的嵌合抗原受体
US20220175897A1 (en) * 2018-12-20 2022-06-09 Oslo Universitetssykehus Hf Chimeric Antigen Receptors (CARS) and Their Use in Medicine
SG10202105790QA (en) * 2018-12-21 2021-07-29 Hoffmann La Roche Antibodies binding to cd3
EP3769816A1 (en) * 2019-07-25 2021-01-27 Ospedale Pediatrico Bambino Gesù Car-cd123 vector and uses thereof
WO2021046451A1 (en) 2019-09-06 2021-03-11 Obsidian Therapeutics, Inc. Compositions and methods for dhfr tunable protein regulation
WO2021260186A1 (en) 2020-06-26 2021-12-30 Juno Therapeutics Gmbh Engineered t cells conditionally expressing a recombinant receptor, related polynucleotides and methods
EP4263600A1 (en) 2020-12-18 2023-10-25 Century Therapeutics, Inc. Chimeric antigen receptor systems with adaptable receptor specificity
IL303270A (en) 2020-12-21 2023-07-01 Allogene Therapeutics Inc The CD45–GATE vehicle activates a protease
KR20230142470A (ko) 2021-01-29 2023-10-11 알로젠 테라퓨틱스 인코포레이티드 동종이계 세포 산물의 T 세포 인식을 완화하기 위한TAP2, NLRC5, β2m, TRAC, RFX5, RFXAP, 및 RFXANK 중 하나 이상의 녹다운 또는 녹아웃
WO2022171195A1 (zh) * 2021-02-11 2022-08-18 兰州大学第二医院 抗cd87抗体与抗pd1抗体联合治疗胃癌
US20240108654A1 (en) 2021-03-03 2024-04-04 Juno Therapeutics, Inc. Combination of a t cell therapy and a dgk inhibitor
WO2023286840A1 (ja) * 2021-07-16 2023-01-19 ノイルイミューン・バイオテック株式会社 抗ＥＧＦＲｖｉｉｉ抗体、ポリペプチド、前記ポリペプチドを発現する細胞、前記細胞を含む医薬組成物、前記細胞の製造方法、及び、前記ポリペプチドをコードする塩基配列を含むポリヌクレオチド又はベクター
WO2023081900A1 (en) 2021-11-08 2023-05-11 Juno Therapeutics, Inc. Engineered t cells expressing a recombinant t cell receptor (tcr) and related systems and methods
WO2024010119A1 (ko) * 2022-07-07 2024-01-11 주식회사 유틸렉스 돌연변이 egfr 및 epha2를 동시 타겟하는 키메라 항원 수용체
WO2024026445A1 (en) 2022-07-29 2024-02-01 Allogene Therapeutics Inc. Engineered cells with reduced gene expression to mitigate immune cell recognition
US20240085403A1 (en) * 2022-08-16 2024-03-14 Allogene Therapeutics, Inc. Method for inhibiting adventitious viral infection
WO2024054944A1 (en) 2022-09-08 2024-03-14 Juno Therapeutics, Inc. Combination of a t cell therapy and continuous or intermittent dgk inhibitor dosing
WO2024100604A1 (en) 2022-11-09 2024-05-16 Juno Therapeutics Gmbh Methods for manufacturing engineered immune cells

Family Cites Families (11)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DE69334095T2 (de) * 1992-07-17 2007-04-12 Dana-Farber Cancer Institute, Boston Verfahren zur intrazellulären Bindung von zielgerichteten Molekülen
US20080045437A1 (en) * 2006-03-10 2008-02-21 Barbara Pfeifer Soap bar with hidden indicia
US20100105136A1 (en) * 2006-10-09 2010-04-29 The General Hospital Corporation Chimeric t-cell receptors and t-cells targeting egfrviii on tumors
US20120079000A1 (en) * 2010-09-27 2012-03-29 Motorola-Mobility, Inc. Selectively receiving media content
MX347078B (es) * 2010-12-09 2017-04-10 Univ Pennsylvania Uso de celulas t modificadas por receptor de antigeno quimerico para tratar cancer.
US9402865B2 (en) * 2011-01-18 2016-08-02 The Trustees Of The University Of Pennsylvania Compositions and methods for treating cancer
IL285335B2 (en) * 2011-04-08 2023-12-01 Us Health Chimeric antigen receptors against epidermal growth factor receptor variant III and their use in cancer treatment
MX367730B (es) * 2012-09-04 2019-09-04 Cellectis Receptor de antigeno quimerico multi-cadena y usos del mismo.
ES2718903T3 (es) * 2012-10-24 2019-07-05 Us Health Receptores de antígenos quiméricos M971
CN105358576B (zh) * 2013-02-20 2020-05-05 诺华股份有限公司 使用人源化抗EGFRvIII嵌合抗原受体治疗癌症
US10287354B2 (en) * 2013-12-20 2019-05-14 Novartis Ag Regulatable chimeric antigen receptor

Also Published As

Publication number Publication date
IL250339A0 (en) 2017-03-30
RU2017102769A (ru) 2018-08-28
KR20170036087A (ko) 2017-03-31
RU2017102769A3 (es) 2018-08-28
AU2015295346A1 (en) 2017-02-16
BR112017001818A2 (pt) 2017-11-21
CN107074973A (zh) 2017-08-18
JP2017522884A (ja) 2017-08-17
WO2016016341A1 (en) 2016-02-04
EP3174556A1 (en) 2017-06-07
KR20180125632A (ko) 2018-11-23
US20170275366A1 (en) 2017-09-28
CA2956307A1 (en) 2016-02-04

Similar Documents

Publication Publication Date Title
MX2017001229A (es) Receptores de antigenos quimericos especificos de egfrviii para inmunoterapia de cancer.
MX2019012244A (es) Receptores de antigeno quimerico especifico de cd123 para inmunoterapia de cancer.
MX2016012855A (es) Receptores de antigeno quimerico especifico de cd33 para inmunoterapia de cancer.
MX367787B (es) Receptores de antígenos quimericos ror1 (ntrkr1) específicos para inmunoterapia del cáncer.
MX2017009181A (es) Receptores de antigenos quimericos de cadena sencilla especificos de anti-cll1 para inmunoterapia de cancer.
PH12018501042A1 (en) Antibodies and antibody fragments for site-specific conjugation
MX2022011659A (es) Proteinas de union a antigeno que se unen a pd-l1.
PH12015502479A1 (en) Cd19 specific chimeric antigen receptor and uses thereof
MX2019001184A (es) Anticuerpos anti-idiotípicos y métodos relacionados.
PH12016502491A1 (en) Bispecific heterodimeric diabodies and uses thereof
MX2020011788A (es) Acoplador trifuncional de antigeno de celulas t y metodos y usos del mismo.
MX2020003046A (es) Anticuerpos anti-hla-a2 y metodos para utilizar los mismos.
MX2015008740A (es) Variantes de regiones fc de igg1 de humano y usos de las mismas.
MX2017006966A (es) Anticuerpos heterodimericos que se unen a cd3 y a antigenos tumorales.
MY175869A (en) Compositions and methods for immunotherapy
MY190711A (en) Treatment of cancer using humanized anti-egfrviii chimeric antigen receptor
MX2016003744A (es) Anticuerpos tem8 y su uso.
MY164647A (en) Cea antibodies
NZ629553A (en) Anti-big-endothelin-1 (big-et-1) antibodies and uses thereof
EP3722313A4 (en) ANTIBODY OR ITS BINDING FRAGMENT TO THE ANTIGEN TO SPECIFICALLY RECOGNIZE A B-CELL MALIGNITY, CHEMERIC ANTIGEN RECEPTOR INCLUDING IT, AND ITS USE
MX2020003047A (es) Nuevos anticuerpos anti-hla-a2 y usos de los mismos.
MX2020003193A (es) Anticuerpos recombinantes mono- o biespecificos multivalentes para fines analiticos.
WO2014016702A3 (en) Humanized forms of monoclonal antibodies to human gnrh receptor
EP3730519A4 (en) ANTIBODY OR ANTIGENT BINDING FRAGMENT THEREOF FOR THE SPECIFIC DETECTION OF B-CELL MALIGNOMAS, CHIMERA ANTIGEN RECEPTOR THEREOF AND USE THEREOF
NZ725519A (en) Combination therapy for treating cancer with a poxvirus expressing a tumor antigen and a monoclonal antibody against tim-3